Clinical trial
Shortness Of Breath Questionnaire Validation Study
NCT00411372 · GlaxoSmithKline, Industry · Withdrawn
Key facts
| NCT number | NCT00411372 |
|---|---|
| Title | Shortness Of Breath Questionnaire Validation Study |
| Official title | A Randomized, Double-blind, Parallel-group Study of Fluticasone Propionate/Salmeterol Combination (FSC 250/50mcg) Twice Daily and Salmeterol (SAL 50mcg) Twice Daily to Validate a New Shortness of Breath Questionnaire in Patients With Chronic Obstructive Pulmonary Disease (COPD) |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Withdrawn |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Pulmonary Disease, Chronic Obstructive |
| Intervention type | Drug |
| Interventions | fluticasone propionate/salmeterol 250/50mcg combination, salmeterol 50mcg |
| Enrollment | 0 |
| Start date | Nov 1, 2006 |
| First posted | Dec 14, 2006 |
| Last update posted | Feb 23, 2015 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: